Although the efficacy of topotecan as second-line chemotherapy for SCLC has been consistently
demonstrated in phase II/III clinical trials, the choice of irinotecan as first-line therapy
prevented use of the evidence-based option.
This pilot study will be conducted to determine the activity and safety of topotecan in SCLC
patients refractory to first-line therapy with irinotecan and platinum.